Introduction {#S1}
============

Osteopontin (OPN) is a phosphoglycoprotein secreted by different cellular types (monocytes, macrophages, cardiac fibroblasts, vascular smooth muscle cells, and endothelial cells), implicated in many molecular and cellular pathophysiological processes, including ectopic calcification ([@B8]). It has been shown that OPN plays an important role in the atherosclerotic plaque formation as well as in coronary artery diseases (CAD) ([@B36]). In particular, several studies showed that circulating OPN levels are elevated in coronary artery disease (CAD) patients ([@B1]; [@B34]; [@B36]; [@B16]) and correlated with the disease extent and severity ([@B21]; [@B17]; [@B36]). Indeed, circulating OPN has been proposed as a predictor of major cardiac events, such as acute myocardial infarction and ischemic heart disease ([@B11]; [@B22]). These observations, taken together with large literature evidences, corroborate the direct link between OPN and CAD development/progression ([@B36]).

In addition, the upregulation of OPN transcription is also driven by oxidative stress ([@B3]) that represents one of the main initial atherosclerotic triggers, leading also to endothelial dysfunction ([@B14]). Indeed, circulating OPN positively correlates with malondialdehyde levels, a recognized biomarker of oxidative stress ([@B4]; [@B12]).

It has also been shown that increased levels of reactive oxygen species, in patients with CAD, lead to a progressive endothelial dysfunction ([@B14]). Furthermore, it has been shown that endothelial vascular function impairment is associated with high OPN levels ([@B27]; [@B26]; [@B2]).

The endothelial dysfunction, among other causes, is associated with the impairment of the nitric oxide (NO) pathway, where the NO synthase (NOS) plays a pivotal role ([@B37]). NOS, using arginine as substrate, produces NO equimolarly to citrulline ([@B19]). Then, NO diffuses locally and mediates endothelium-dependent vasodilatation, acting on adhesion molecules and avoiding the infiltration of inflammatory cells and subsequent detrimental effects ([@B33]). Undeniably, the reduction of NO bioavailability have a crucial importance in cardiovascular diseases ([@B6]; [@B10]). Thus, in this study, we investigated the link between circulating OPN, oxidative stress, and endothelial dysfunction. We, therefore, performed an association study to explore the dysregulation of the arginine pathway and different oxidative stress markers in patients with overt CAD requiring surgical myocardial revascularization.

Materials and Methods {#S2}
=====================

Study Population {#S2.SS1}
----------------

Thirty-three patients that underwent coronary artery bypass grafting (CABG) and twenty-five control subjects were enrolled in the study between January and June 2011 at Centro Cardiologico Monzino IRCCS. Pre-operative inclusion criteria were isolated surgical myocardial revascularization, elective surgery, age more than 18 years old, ejection fraction \>30% and normal sinus rhythm. Exclusion criteria were prior cardiac surgery, rheumatic heart disease, endocarditis, active malignancy, chronic liver, and kidney diseases, calcium regulation disorders (hyperparathyroidism, hyperthyroidism and hypothyroidism) and chronic or acute inflammatory states (sepsis, autoimmune disease and inflammatory bowel disease). The Institutional Review Board and Ethical Committee of Centro Cardiologico Monzino (IRCCS) approved the study. Written informed consent to participate in this prospective observational study was obtained from all enrolled patients. The study protocol was conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

Blood and Urine Sampling {#S2.SS2}
------------------------

Whole blood: 6 mL of peripheral blood sample was drawn from patients while fasting, into tubes containing EDTA (9.3 mM, Vacutainer Systems, Becton Dickinson, Franklin Lakes NJ, United States) kept on ice. 250 μL of whole blood was immediately precipitated with 250 μL of 10% trichloroacetic acid (Sigma-Aldrich, Darmstadt, Germany) plus 1 mM EDTA solution. Samples were stored at −80°C until analysis.

Plasma EDTA: anti-coagulated EDTA blood was centrifuged at 1700 g for 10 min at 4°C within 30 min after being drawn. Plasma was separated and aliquots were stored at −80°C until analysis.

Urine: urine collection was carried out the night before surgery or the night before the visit and samples stored at −80°C until analysis.

Osteopontin Evaluation {#S2.SS3}
----------------------

Plasma levels of soluble OPN were measured with an enzyme-linked immunosorbent assay (ELISA) kit (Quantikine, R&D) following manufacturer instructions.

Oxidative Stress Markers Measurement {#S2.SS4}
------------------------------------

Reduced (GSH) and oxidized glutathione (GSSG) forms were determined in whole blood by liquid chromatography-tandem mass spectrometry (LC-MS/MS) method ([@B30]; [@B35]). The separation of analytes was conducted on a Luna PFP analytical column (100 mm × 2.0 mm, 3 m, Phenomenex) maintained at 35°C under isocratic conditions (flow rate of 250 μL/min, mobile phase:1% methanol in 0.75 mM ammonium formate adjusted to pH 3.5 with formic acid). LC-MS/MS analysis was performed using an Accela HPLC (high performance liquid chromatography) system coupled with a triple quadrupole mass spectrometer TSQ Quantum Access (Thermo Fisher Scientific, Waltham, MA, United States) equipped with an electrospray ionization (ESI) source working in multiple reaction monitoring (MRM) and in positive ionization mode.

Data were obtained after comparison with calibration curves using GSH and GSSG pure standard solutions (Sigma-Aldrich, Darmstadt, Germany). The intra- and inter-CVs (%) obtained with standard samples were \<5% for both the analytes. The limits of detection were 0.031 μmol/L for GSH and 0.008 μmol/L for GSSG. Levels of GSH and GSSG were corrected for haemoglobin (Hb) and expressed as μmol/g Hb.

Urinary 2,3-dinor-8isoPGF2a was detected by LC-MS/MS method according to [@B5]. The urinary concentration was calculated from the area ratio of the ion peaks of the 2,3-dinor-8isoPGF2a over the deuterated standard (8-iso-PGF2a-d4). The estimated values were corrected for the urinary creatinine levels and expressed as pg/mg of creatinine.

Arginine Pathway Analytes Measurement {#S2.SS5}
-------------------------------------

The assessment of arginine, ornithine, citrulline, asymmetric dimethylarginines (ADMA), and symmetric dimethylarginine (SDMA) was performed by LC-MS/MS using a target metabolomic approach ([@B31]). Briefly, the chromatographic analysis was conducted on a Luna HILIC (hydrophilic interaction liquid chromatography) analytical column (50 mm × 2.0 mm, 3 μm, Phenomenex, Torrance, CA, United States). The mobile phases consisted of aqueous 1.5 mM ammonium formate (pH 3.2) (A) and 1.5 mM ammonium formate in acetonitrile/methanol (95.5:0.5, v/v) (pH 3.2) (B) at a flow rate of 250 μL/min. The mobile phase gradient ran from 10% A to 70% A over 7 min, from 70% A to 94.5% A over 2 min and was held at 94.5% A for 5 min, returning to 10% A over 2 min and held at 10% A for re-equilibration. The sample injection volume was 10 μL and the column temperature was set at 30°C. Total run time per sample, including column cleaning and re-equilibration, was 25 min. The mass spectrometric analysis was performed using a TSQ Quantum Access (Thermo Fisher Scientific, Waltham, MA, United States) triple quadrupole mass spectrometer equipped with ES) interface operating in MRM and positive ionization mode. The LOQ value is 0.25 M for all compounds, making this method suitable for the analysis of samples containing relatively low concentrations of the analytes, with a satisfactory precision as documented by the intra- and inter-day CVs of less than 10%. The method is linear in a wide range of concentrations (between 0 and 20 μM), with correlation coefficients greater than 0.99 and limit of detection (LOD) around 3--10 nm for all compounds. Global arginine bioavailability (GABR) was calculated as the ratio of arginine levels and the total amount of ornithine plus citrulline levels. GABR is an index of circulating arginine bioavailability associated with markers of endothelial dysfunction and increased risk of cardiovascular mortality ([@B18]; [@B29]).

Statistical Analyses {#S2.SS6}
--------------------

Continuous variables were analyzed using Student's *T*-test and summarized as mean ± SD, while categorical ones were analyzed using Chi-square test and summarized as frequency (n) and percentage (%). Circulating biomarkers were analyzed by the Pearson product-moment correlation coefficient (*r*~*p*~) and plotted using Graphpad Prism v7.0. A value of *p* ≤ 0.05 was deemed statistically significant.

Results {#S3}
=======

Demographic and clinical characteristics, as well as pharmacological therapies of the study population are listed in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. As previously reported by other authors ([@B34]; [@B36]; [@B16]), circulating OPN levels were lower in controls compared to the CAD patients (57.76 ± 9.8 vs 68.37 ± 24.2 pg/ml, respectively, *p* = 0.04, [Supplementary Figure S1](#SM1){ref-type="supplementary-material"}).

Osteopontin and Oxidative Stress {#S3.SS1}
--------------------------------

We assess the possible relationship between OPN levels and oxidative stress status, represented by 2,3-dinor-8isoPGF2a and the ratio between the reduced (GSH) and the oxidized (GSSG) forms of glutathione, in patients before the surgical intervention.

Linear regression analysis reported that there was no significant association between OPN levels and GSH/GSSG ratio, in controls (*r*~*p*~ = 0.002, *p* = 0.99, [Supplementary Figure S2A](#SM1){ref-type="supplementary-material"}), as well as in CAD patients (*r*~*p*~ = −0.15, *p* = 0.42, [Figure 1A](#F1){ref-type="fig"}). The same analysis showed that there was no association between OPN levels and 2,3-dinor-8isoPGF2a urine levels in control group (*r*~*p*~ = −0.38, *p* = 0.08, [Supplementary Figure S2B](#SM1){ref-type="supplementary-material"}). However, OPN levels were directly correlated with 2,3-dinor-8isoPGF2a urine levels in CAD patients (*r*~*p*~ = 0.42, *p* = 0.02, [Figure 1B](#F1){ref-type="fig"}).

![Linear regression analyses between osteopontin (OPN) and GSH/GSSG ratio **(A)** and 2,3-dinor-8isoPGF2a **(B)**.](fphys-11-00982-g001){#F1}

Osteopontin and Arginine Pathway Metabolites {#S3.SS2}
--------------------------------------------

Since arginine is the substrate of NOS, we evaluated the metabolites involved in arginine pathway as representative molecules of NO production ([@B19], [@B20]). In the control group, there were no correlations between the considered metabolites and circulating OPN levels (arginine, *r*~*p*~ = −0.33, *p* = 0.11, ornithine, *r*~*p*~ = −0.04, *p* = 0.85, citrulline, *r*~*p*~ = 0.07, *p* = 0.75, ADMA, *r*~*p*~ = −0.30, *p* = 0.14, SDMA, *r*~*p*~ = −0.23, *p* = 0.28, GABR, *r*~*p*~ = 0.30, *p* = 0.14, [Supplementary Figure S3](#SM1){ref-type="supplementary-material"}). In CAD patients, the linear regressions showed that OPN levels were not associated with arginine levels (*r*~*p*~ = 0.20, *p* = 0.27, [Figure 2A](#F2){ref-type="fig"}) and the global arginine bioavailability (GABR, *r*~*p*~ = −0.29, *p* = 0.11, [Figure 2F](#F2){ref-type="fig"}). However, OPN levels were positively correlated with ornithine (*r*~*p*~ = 0.44, *p* = 0.01, [Figure 2B](#F2){ref-type="fig"}), ADMA (*r*~*p*~ = 0.54, *p* = 0.001, [Figure 2D](#F2){ref-type="fig"}), and SDMA (*r*~*p*~ = 0.37, *p* = 0.03, [Figure 2E](#F2){ref-type="fig"}) levels.

![Linear regression analyses between osteopontin (OPN) and arginine **(A)**, ornithine **(B)**, Citrulline **(C)**, asymmetric dimetilarginine \[ADMA, **(D)**\], symmetric dimethilarginine \[SDMA, **(E)**\], and global arginine bioavailability \[GABR, **(F)**\].](fphys-11-00982-g002){#F2}

In addition, a positive correlation was found between OPN and citrulline (*r*~*p*~ = 0.45, *p* = 0.008, [Figure 2C](#F2){ref-type="fig"}). Citrulline is known to be produced by (i) NOS from arginine, equimolarly with NO, (ii) ornithinetranscarbamilase (OTC) form ornithine, and (iii) dimethylarginine dimethylaminohydrolase (DDAH) from ADMA. In this regard, citrulline was not associated with ornithine (*r*~*p*~ = 0.18, *p* = 0.33, [Figure 3A](#F3){ref-type="fig"}), although, we found that citrulline levels were associated with ADMA (*r*~*p*~ = 0.40, *p* = 0.02, [Figure 3B](#F3){ref-type="fig"}) levels.

![Linear regression analyses between citrulline and ornithine **(A)** and asymmetric dimetilarginine \[ADMA, **(B)**\].](fphys-11-00982-g003){#F3}

Discussion {#S4}
==========

To our knowledge, we show for the first time that OPN could be linked to the pathological dysregulation of the arginine pathway in CAD patients.

As largely reported before also CAD patients in our cohort showed high levels of circulating OPN. Nonetheless, CAD patients were characterized by an increased oxidative stress status and impaired endothelial function associated with a NO bioavailability reduction ([@B1]; [@B37]; [@B14]). Recently some authors reported that high OPN levels could in some way interfere with vessel endothelial function ([@B27]; [@B2]; [@B16]). -- In this study, we investigated the relationship between OPN, oxidative stress, and endothelial dysfunction taking into account the arginine metabolism. In our cohort, plasma OPN levels correlated with urinary 2,3-dinor-8isoPGF2a, in agreement with literature evidences on the intensified production of OPN caused by an increased systemic oxidative stress status. However, we did not see any significant association between plasma OPN and GSH/GSSG ratio. These data suggest that lipid peroxidation may be the main process induced by the oxidative stress in the context of CAD, instead of protein oxidation. The link between OPN and lipid peroxidation is corroborated by the lack of any association between OPN and 2,3-dinor-8isoPGF2a in the control group.

It has been shown that OPN could interfere with the arginine pathway by inhibiting the inducible form of the NOS (iNOS) enzyme ([@B28]; [@B25]). Thus, it is likely that the same mechanisms could cause an inhibition of endothelial NOS (eNOS) enzyme as a result of increased OPN levels. In this scenario, the reduction of NO synthesis, in combination with increased oxidative stress status, would favor the atherosclerotic milieu ([@B15]). For this purpose, we analyzed the metabolites of the arginine pathway both in controls and CAD patients. We found no correlation between OPN and any metabolite in control group, while in the in CAD patients, we found that OPN directly correlated with several metabolites belonging to the arginine pathway. Indeed, we found positive correlations between OPN, ADMA, SDMA, and ornithine. SDMA is not only an inhibitor of the arginine transporter CAT ([@B9]), but also a pro-inflammatory molecule ([@B7]), like OPN ([@B13]). In the context of CAD, SDMA could play both roles acting in synergy with OPN in the development of the inflammation. However, we also observed positive correlations between citrulline and OPN. To explain this last correlation, we have to take into account that citrulline is normally produced equimolarly to NO from arginine by eNOS, but other sources of its production are known ([@B19]). In particular, citrulline could derive from ADMA by DDAH activity. Indeed, in our cohort we found a positive correlation between citrulline and ADMA, indicating that high levels of citrulline could be due to the activity of DDAH enzyme.

In 2012, [@B27] showed, in CAD patients, an improved endothelial functionality probably due to the inhibition of arginase. This evidence suggests that arginase activation reduces arginine bioavailability, thus NOS-mediated NO production, fundamental to maintain the endothelial function. Of notice, it has been reported a possible interaction between OPN and arginase ([@B23]). Thus, it is likely that OPN could stimulate arginase activity in the CAD context.

We strongly believe that OPN could be directly or indirectly implicated in the decreased activity of eNOS in atherosclerosis, contributing to the endothelial dysfunction typically observed in CAD patients. We therefore propose a schematic view of the possible components that could link OPN to the arginine metabolism ([Figure 4](#F4){ref-type="fig"}).

![Proposed molecular pathway. OPN, osteopontin, SDMA, symmetric dimethilarginine, ADMA, asymmetric dimetilarginine, CAT, cationic aminoacid transporter, OTC, ornithinetranscarbamilase, DDAH, dimethylarginine dimethylaminohydrolase, ROS, reactive oxygen species.](fphys-11-00982-g004){#F4}

In summary, our results showed a correlation between OPN levels, oxidative stress status, and endothelial dysfunction markers in CAD patients. Nonetheless, further studies are required to determine if OPN really drives the endothelial dysfunction by direct or indirect eNOS inhibition in CAD patients. Endothelial cells from coronary artery, genetically modified to silence or overexpress OPN, could be the appropriate *in vitro* model to determine the functionality of the enzymes involved in the NO/arginine pathway. While OPN knockout mice would represent the best *in vivo* model to evaluate the relationship between the NO/arginine pathway and the OPN ([@B24]).

Limitations {#S4.SS1}
-----------

This study has different limitations. First, we could not investigate the influence of each pharmacological treatment on the analyzed metabolites due to our small cohort. Second, we could not measure eNOS, arginase, and DDAH levels and activity. Third, although flow mediated dilation (FMD) is a recognized technique to assess endothelial dysfunction, we could not evaluate it given the status of our patients before surgery, as well as high number of drugs taken as per the 2019 European Society of Cardiology (ESC) guidelines for FMD evaluation ([@B32]). Lastly, we have not measured other common oxidative stress markers, such as malondialdehyde, since we wanted to investigate the glutathione system and the lipid peroxidation. Our study showed an association between OPN and endothelial dysfunction, however, further studies are necessary to prove the cause-effect relationship in CAD patients.
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